Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

Delayed Quote. Delayed  - 08/31 10:00:00 pm
26.07 USD   -4.19%
07/26 SAREPTA THERAPE : Announces Second Quarter 2016 Financial Results an..
07/19 SAREPTA THERAPE : reports 2Q loss
07/19 SAREPTA THERAPE : Announces Second Quarter 2016 Financial Results an..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sarepta Therapeutics Inc : SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/24/2013 | 03:05pm CEST

New York, NY - (ACCESSWIRE) - 09/24/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Facebook, Inc. (NASDAQ:FB), Cirrus Logic Inc. (NASDAQ:CRUS), and Omeros Corporation (NASDAQ:OMER)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases closed up in its previous session (+10.79%) on 6,581,320 shares traded after Sarepta was upgraded to Overweight from Neutral at Piper Jaffray. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is currently up (+251.61%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=SRPT&SubId=AW

Facebook, Inc. (NASDAQ:FB) operates as a social networking company worldwide closed down in its previous session (-0.63%) on 75,274,915 shares traded after Facebook Quietly Rolls Out Its Mobile Payments Autofill Product, AllThingsD Reported. Facebook, Inc. (NASDAQ:FB) is currently down (-2.75%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Facebook, Inc. (NASDAQ:FB)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=FB&SubId=AW

Cirrus Logic Inc. (NASDAQ:CRUS) a fabless semiconductor company that develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets closed up in its previous session (+5.41%) on 6,219,309 shares traded after CIRRUS LOGIC INC Filed SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year. Cirrus Logic Inc. (NASDAQ:CRUS) is currently up (+46.96%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Cirrus Logic Inc. (NASDAQ:CRUS)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CRUS&SubId=AW

Omeros Corporation (NASDAQ:OMER) a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system closed up in its previous session (+28.21%) on 8,095,031 shares traded after Omeros has been Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference on Friday, September 27, 2013. Omeros Corporation (NASDAQ:OMER) is currently up (+167.95%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Omeros Corporation (NASDAQ:OMER)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=OMER&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAREPTA THERAPEUTICS INC
08/09 SAREPTA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
07/28 SAREPTA THERAPEUTICS : Announces Second Quarter 2016 Financial Results and Recen..
07/26 SAREPTA THERAPEUTICS : Announces Second Quarter 2016 Financial Results and Recen..
07/21 SAREPTA THERAPEUTICS : Assigned Patent
07/19 SAREPTA THERAPEUTICS : reports 2Q loss
07/19 SAREPTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fina..
07/19 SAREPTA THERAPEUTICS : Announces Second Quarter 2016 Financial Results and Recen..
07/07 SAREPTA THERAPEUTICS : Assigned Patent
07/01 SAREPTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financia..
06/28 SAREPTA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders..
More news
Sector news : Bio Therapeutic Drugs
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/25 Mallinckrodt's Synacthen Depot Fast Track'd for Duchenne muscular dystrophy
08/16 SNIPPET ROUNDUP : Biogen Buy Rumours, CVS Cuts And Spark Gains On Shire's Loss
08/11 SAREPTA : The Competition Is At The Gate
08/10 FDA accepts Marathon Pharma's NDAs for Duchenne candidate deflazacort under a..
08/04 Sarepta Dystrophin Levels For Duchenne Muscular Dystrophy Drug
Advertisement
Financials ($)
Sales 2016 13,9 M
EBIT 2016 -229 M
Net income 2016 -245 M
Debt 2016 10,2 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 94,4x
EV / Sales 2017 18,2x
Capitalization 1 303 M
More Financials
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | SRPT | US8036071004 | 4-Traders
Full-screen chart
Technical analysis trends SAREPTA THERAPEUT...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 21,0 $
Spread / Average Target -23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edward M. Kaye Senior VP, Chief Executive & Medical Officer
M. Kathleen Behrens Chairman
Gavin T. Malenfant Head-Operations & Vice President
Sandesh Mahatme Chief Financial Officer & Senior Vice President
Gil Price Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS I..-29.47%1 303
AMGEN, INC.5.19%127 790
GILEAD SCIENCES, INC.-23.00%102 828
CELGENE CORPORATION-10.64%82 953
REGENERON PHARMACEUTIC..-27.20%41 614
VERTEX PHARMACEUTICALS..-23.87%23 737
More Results